English

Eligibility Metastatic Colorectal Cancer NCT01925274

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
kras and nras wild type metastatic colorectal cancer
Description

Secondary malignant neoplasm of large intestine KRAS Wild Type | Secondary malignant neoplasm of large intestine NRAS Wild Type

Data type

boolean

Alias
UMLS CUI [1,1]
C0346973
UMLS CUI [1,2]
C1537502
UMLS CUI [1,3]
C1883559
UMLS CUI [2,1]
C0346973
UMLS CUI [2,2]
C0809246
UMLS CUI [2,3]
C1883559
progression following treatment for colorectal cancer with irinotecan, oxaliplatin and fluoropyrimidine therapy in the metastatic setting.
Description

Disease Progression | Status post Treatment Secondary malignant neoplasm of large intestine | irinotecan | oxaliplatin | fluoropyrimidine

Data type

boolean

Alias
UMLS CUI [1]
C0242656
UMLS CUI [2,1]
C0231290
UMLS CUI [2,2]
C0087111
UMLS CUI [2,3]
C0346973
UMLS CUI [3]
C0123931
UMLS CUI [4]
C0069717
UMLS CUI [5]
C0596581
eastern cooperative oncology group [ecog] performance status of 0, 1, or 2
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
at least one measurable lesion by response evaluation criterion in solid tumors [recist]
Description

Measurable lesion Quantity

Data type

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C1265611
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
more than 2 prior cytotoxic chemotherapy regimens for metastatic colorectal cancer.
Description

Cytotoxic Chemotherapy Quantity Secondary malignant neoplasm of large intestine

Data type

boolean

Alias
UMLS CUI [1,1]
C0677881
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0346973
prior treatment with a pi3k, mtor, akt or egfr inhibitor
Description

PI3K Inhibitor | mTOR Inhibitor | AKT1 gene Inhibitor | AKT2 gene Inhibitor | AKT3 gene Inhibitor | EGFR inhibitor

Data type

boolean

Alias
UMLS CUI [1]
C1519050
UMLS CUI [2]
C2746052
UMLS CUI [3,1]
C0812228
UMLS CUI [3,2]
C1999216
UMLS CUI [4,1]
C0812230
UMLS CUI [4,2]
C1999216
UMLS CUI [5,1]
C1332074
UMLS CUI [5,2]
C1999216
UMLS CUI [6]
C1443775
patients who have discontinued treatment with prior irinotecan therapy due to toxicity.
Description

Irinotecan Discontinued | Etiology Toxicity

Data type

boolean

Alias
UMLS CUI [1,1]
C0123931
UMLS CUI [1,2]
C1444662
UMLS CUI [2,1]
C0015127
UMLS CUI [2,2]
C0600688
prior radiation to the pelvis or abdomen
Description

Radiotherapy to pelvis | Radiotherapy to abdomen

Data type

boolean

Alias
UMLS CUI [1]
C1536155
UMLS CUI [2]
C1997554
patients with history of interstitial lung disease.
Description

Lung Diseases, Interstitial

Data type

boolean

Alias
UMLS CUI [1]
C0206062
Back to the top of the page

Similar models

Eligibility Metastatic Colorectal Cancer NCT01925274

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Secondary malignant neoplasm of large intestine KRAS Wild Type | Secondary malignant neoplasm of large intestine NRAS Wild Type
Item
kras and nras wild type metastatic colorectal cancer
boolean
C0346973 (UMLS CUI [1,1])
C1537502 (UMLS CUI [1,2])
C1883559 (UMLS CUI [1,3])
C0346973 (UMLS CUI [2,1])
C0809246 (UMLS CUI [2,2])
C1883559 (UMLS CUI [2,3])
Disease Progression | Status post Treatment Secondary malignant neoplasm of large intestine | irinotecan | oxaliplatin | fluoropyrimidine
Item
progression following treatment for colorectal cancer with irinotecan, oxaliplatin and fluoropyrimidine therapy in the metastatic setting.
boolean
C0242656 (UMLS CUI [1])
C0231290 (UMLS CUI [2,1])
C0087111 (UMLS CUI [2,2])
C0346973 (UMLS CUI [2,3])
C0123931 (UMLS CUI [3])
C0069717 (UMLS CUI [4])
C0596581 (UMLS CUI [5])
ECOG performance status
Item
eastern cooperative oncology group [ecog] performance status of 0, 1, or 2
boolean
C1520224 (UMLS CUI [1])
Measurable lesion Quantity
Item
at least one measurable lesion by response evaluation criterion in solid tumors [recist]
boolean
C1513041 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Cytotoxic Chemotherapy Quantity Secondary malignant neoplasm of large intestine
Item
more than 2 prior cytotoxic chemotherapy regimens for metastatic colorectal cancer.
boolean
C0677881 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0346973 (UMLS CUI [1,3])
PI3K Inhibitor | mTOR Inhibitor | AKT1 gene Inhibitor | AKT2 gene Inhibitor | AKT3 gene Inhibitor | EGFR inhibitor
Item
prior treatment with a pi3k, mtor, akt or egfr inhibitor
boolean
C1519050 (UMLS CUI [1])
C2746052 (UMLS CUI [2])
C0812228 (UMLS CUI [3,1])
C1999216 (UMLS CUI [3,2])
C0812230 (UMLS CUI [4,1])
C1999216 (UMLS CUI [4,2])
C1332074 (UMLS CUI [5,1])
C1999216 (UMLS CUI [5,2])
C1443775 (UMLS CUI [6])
Irinotecan Discontinued | Etiology Toxicity
Item
patients who have discontinued treatment with prior irinotecan therapy due to toxicity.
boolean
C0123931 (UMLS CUI [1,1])
C1444662 (UMLS CUI [1,2])
C0015127 (UMLS CUI [2,1])
C0600688 (UMLS CUI [2,2])
Radiotherapy to pelvis | Radiotherapy to abdomen
Item
prior radiation to the pelvis or abdomen
boolean
C1536155 (UMLS CUI [1])
C1997554 (UMLS CUI [2])
Lung Diseases, Interstitial
Item
patients with history of interstitial lung disease.
boolean
C0206062 (UMLS CUI [1])
Back to the top of the page